Rekombinanter ITGA4 (Natalizumab Biosimilar) Antikörper

Produktnummer ABIN5668196

Dieses Human Monoklonal-Antikörper erkennt spezifisch ITGA4 (Natalizumab Biosimilar) in FACS und BR. Er zeigt eine Reaktivität gegenüber Human und wurde in 1 Publikation erwähnt.

Kurzübersicht für Rekombinanter ITGA4 (Natalizumab Biosimilar) Antikörper (ABIN5668196)

Target: ITGA4 (Natalizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Human

Klonalität: Monoklonal

Konjugat: Dieser ITGA4 (Natalizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Blocking Reagent (BR)

Produktdetails anti-ITGA4 (Natalizumab Biosimilar) Antikörper

Verwendungszweck: Anti-Integrin alpha 4 [Natalizumab], Human IgG4, kappa

Spezifität: This antibody binds to the alpha 4 binds subunit of α4β1 (also known as very late antigen 4 [VLA-4] or CD49d-CD29) and α4β7 integrin

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG4

Aufreinigung: Protein A affinity purified

Reinheit: > 98 % as determined by SDS-PAGE

Endotoxin-Niveau: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: The RAMOS cell line, a non-EBV releasing cell line, injected into mice.

Isotyp: IgG4 kappa

Anwendungsinformationen

Applikationshinweise: This antibody binds to human integrin alpha 4 and has been used to treat Multiple Sclerosis and Crohn's Disease.

Kommentare:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Referenzen für anti-ITGA4 (Natalizumab Biosimilar) Antikörper (ABIN5668196)

Cegarra, Cameron, Chaves, Dabdoubi, Do, Genêt, Roudières, Shi, Tchepikoff, Lesuisse: "An innovative strategy to identify new targets for delivering antibodies to the brain has led to the exploration of the integrin family." in: PloS one, Vol. 17, Issue 9, pp. e0274667, (2022) (PubMed).

Details zu ITGA4 (Natalizumab Biosimilar)

Target: ITGA4 (Natalizumab Biosimilar)

Hintergrund: CD49D, alpha 4 subunit of VLA-4 receptor, ITGA4, Integrin alpha-IV

UniProt: P13612